Table 1 Patient characteristics at diagnosis of brain metastasis.
From: Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases
Factor | Total (N = 521) | No-ICI (N = 325) | ICI-90 (N = 68) | G90 (N = 128) | p value overall/No-ICI vs IC-I90 |
|---|---|---|---|---|---|
Age | 62.7 [56.9, 70.6] | 63.0 [57.1, 70.7] | 60.4 [54.1, 70.3] | 62.2 [57.1, 70.3] | 0.29 |
Age, ≥ 65 | 214 (41.1) | 139 (42.8) | 22 (32.4) | 53 (41.4) | 0.28 |
Sex: male | 262 (50.3) | 174 (53.5) | 32 (47.1) | 56 (43.8) | 0.15 |
Race: white | 439 (84.3) | 272 (83.7) | 55 (80.9) | 112 (87.5) | 0.43 |
KPS | 80.0 [80.0, 90.0] | 80.0 [70.0, 90.0] | 80.0 [70.0, 90.0] | 90.0 [80.0, 90.0] | < 0.001/0.86 |
KPS ≥ 90 | < 0.001 | ||||
< 90 | 221 (42.4) | 140 (43.1) | 38 (55.9) | 43 (33.6) | |
≥ 90 | 220 (42.2) | 112 (34.5) | 29 (42.6) | 79 (61.7) | |
Unknown | 80 (15.4) | 73 (22.5) | 1 (1.5) | 6 (4.7) | |
Lesion number | 2.0 [1.00, 3.0] | 1.00 [1.00, 3.0] | 2.0 [1.00, 3.0] | 2.0 [1.00, 3.0] | 0.27 |
Lesion ≥ 2 | 261 (50.3) | 153 (47.4) | 37 (54.4) | 71 (55.5) | 0.23 |
Number of SRS | 1.00 [1.00, 2.0] | 1.00 [1.00, 2.0] | 1.00 [1.00, 2.0] | 2.0 [1.00, 2.0] | < 0.001/0.64 |
SRS ≥ 2 | 164 (32.2) | 81 (25.7) | 17 (25.4) | 66 (52.0) | < 0.001 |
Histology: adenocarcinoma | 371 (73.9) | 216 (70.6) | 52 (76.5) | 103 (80.5) | 0.089 |
EC-mets | 238 (46.6) | 139 (44.0) | 37 (55.2) | 62 (48.4) | 0.22 |
WBRT | 131 (25.1) | 86 (26.5) | 11 (16.2) | 34 (26.6) | 0.19 |
KRAS status | < 0.001/< 0.001 | ||||
Negative | 109 (20.9) | 50 (15.4) | 16 (23.5) | 43 (33.6) | |
Positive | 98 (18.8) | 39 (12.0) | 23 (33.8) | 36 (28.1) | |
Missing | 314 (60.3) | 236 (72.6) | 29 (42.6) | 49 (38.3) | |
PDL1 status | < 0.001/< 0.001 | ||||
Negative | 30 (5.8) | 16 (4.9) | 4 (5.9) | 10 (7.8) | |
Positive | 93 (17.9) | 27 (8.3) | 40 (58.8) | 26 (20.3) | |
Missing | 398 (76.4) | 282 (86.8) | 24 (35.3) | 92 (71.9) |
